Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss

Pier Edoardo Rovatti, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, outlines the ability of anti CD3 x CD33 bispecific antibodies to redirect donor T-cells against HLA loss in leukemia relapses. Dr Rovatti discusses how anti-CD3 x CD33 bispecific antibodies can effectively redirect donor T-cells against HLA loss leukemia variants which is results in their rapid killing. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).